Cost-Effectiveness of Pembrolizumab Regimens for the First-Line Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma in Argentina

被引：0
|
作者：
Victoria Wurcel
Diana Chirovsky
Rebekah Borse
Juan Ignacio Altuna
Fernando Carabajal
Jyotika Gandhi
机构：
[1] MSD Argentina,
[2] Merck & Co.,undefined
[3] Inc.,undefined
[4] CHEORS,undefined
来源：
Advances in Therapy | 2021年 / 38卷
关键词：
Argentina; Cetuximab; Cost-effectiveness; Head and neck squamous cell carcinoma; Latin America; Pembrolizumab;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：2613 / 2630
页数：17
相关论文
共 50 条
  • [31] RAMUCIRUMAB IN COMBINATION WITH PEMBROLIZUMAB AS FIRST-LINE TREATMENT FOR RECURRENT OR METASTATIC HEAD AND NECK SQUAMOUS-CELL CARCINOMA: A PHASE 1-2 TRIAL
    Adkins, Douglas
    Ley, Jessica
    Palka, Kevin
    Jacobs, Miriam
    Liu, Jingxia
    Oppelt, Peter
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 : A385 - A385
  • [32] COST-EFFECTIVENESS OF CETUXIMAB (ERBITUXIM) FOR THE FIRST LINE TREATMENT OF SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK (SCCHN) IN CANADA
    Sambrook, J. C.
    Levy, A. R.
    Johnston, K. M.
    Ricard, N. J.
    Bourgault, C.
    Donato, B. M.
    Hotte, S. J.
    Chasen, M. R.
    Briggs, A.
    VALUE IN HEALTH, 2009, 12 (03) : A49 - A49
  • [33] Cost-effectiveness Analysis of Nivolumab for Treatment of Platinum-Resistant Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
    Tringale, Kathryn R.
    Carroll, Kate T.
    Zakeri, Kaveh
    Sacco, Assuntina G.
    Barnachea, Linda
    Murphy, James D.
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2018, 110 (05): : 479 - 485
  • [34] Cost-effectiveness of nivolumab for treatment of platinum-resistant recurrent or metastatic squamous cell carcinoma of the head and neck.
    Carroll, Kate
    Tringale, Kathryn Ries
    Zakeri, Kaveh
    Sacco, Assuntina Gesualda
    Barnachea, Linda
    Murphy, James Don
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [35] First-line versus second-line immunotherapy in recurrent/metastatic squamous cell carcinoma of the head and neck
    Even, C.
    Torossian, N.
    Ibrahim, T.
    Martin, N.
    Badis, L. Mayache
    Ferrand, F. R.
    Iacob, M.
    Guigay, J.
    Le Tourneau, C.
    Daste, A.
    Saada-Bouzid, E.
    Saleh, K.
    ANNALS OF ONCOLOGY, 2019, 30
  • [36] Pembrolizumab and afatinib for recurrent or metastatic head and neck squamous cell carcinoma
    Kao, H-F.
    Hong, R-L.
    ANNALS OF ONCOLOGY, 2018, 29 : 379 - 379
  • [37] Pembrolizumab and afatinib for recurrent or metastatic head and neck squamous cell carcinoma
    Kao, Hsiang-Fong
    Huang, Huai-Cheng
    Liao, Bin-Chi
    Hong, Ruey-Long
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2017, 5
  • [38] First-Line Tislelizumab for Advanced or Metastatic Esophageal Squamous Cell Carcinoma:A Cost-Effectiveness Analysis
    Zheng, Zhiwei
    Chen, Hongcai
    Cai, Hongfu
    Zhu, Huide
    EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2024, 24 (03) : 397 - 404
  • [39] Cetuximab: a standard approach to the first-line treatment of recurrent and/or metastatic and locally advanced squamous cell carcinoma of the head and neck
    Bernier, Jacques
    ONCOLOGY REVIEWS, 2009, 3 (04) : 247 - 256
  • [40] Cost-effectiveness of pembrolizumab in combination with axitinib as first-line treatment for advanced renal cell carcinoma
    Bensimon, Arielle G.
    Zhong, Yichen
    Swami, Umang
    Briggs, Allison
    Young, Joshua
    Feng, Yuan
    Song, Yan
    Signorovitch, James
    Adejoro, Oluwakayode
    Chakravarty, Abhiroop
    Chen, Mei
    Perini, Rodolfo F.
    Geynisman, Daniel M.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
12345